secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001193125-24-049260
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics closes $51M private placement to fund Phase 3 study of cadisegliatin
--------------------------------------------------------------------------------

- Closed $51M private placement with institutional investors (Samsara BioCapital, JDRF T1D Fund) at $11.81/share (45-day VWAP).
- Issued 464,377 shares and pre-funded warrants for 3,853,997 shares at $0.01 exercise price.
- Proceeds to fully fund first Phase 3 study of cadisegliatin (TTP399) for type 1 diabetes, expected to start mid-2024.
- Board reduced from 9 to 7 members; lead investors to designate three directors; Srinivas Akkaraju (Samsara) appointed.
- CEO Paul Sekhri's salary increased to $650,000 from $480,000; granted option for 89,212 shares at $11.81.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/0001193125-24-049260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000119312524049260/d754681d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-049260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer